开始的年龄查代谢功能障碍相关的乳脂性肝病在儿童使用控制减弱参数在过渡弹性显微镜上
Li-Wen Lee1,2, Jrhau Lung2,3,4, Ju-Bei Yen5,6
1Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Pediatric obesity
|December 22, 2025
概括
儿童脂肪肝疾病的早期查至关重要. 代谢功能障碍相关的肥胖性肝病 (MASLD) 查应在肥胖儿童的第一年级开始,在超重儿童的第六年级开始.
科学领域:
- 儿科胃肠病学和肝病学
- 公共卫生和预防医学.
- 儿童肥胖和代谢健康问题
背景情况:
- 儿童肥胖率的上升与久坐不动的行为以及含糖饮料和超加工食品的消费增加有关.
- 这种趋势增加了儿童肥胖的风险,并加快了儿童肥胖的发病速度.
- 儿童肥胖是发展非酒精性脂肪性肝病的重要危险因素,现在被称为代谢功能障碍相关的脂肪性肝病 (MASLD).
研究的目的:
- 为了确定控制减弱参数 (CAP) 截止值,以识别健康儿童肝脏肥胖症.
- 确定超重和肥胖儿童中MASLD的患病率.
- 确定儿童群体中MASLD查的最佳起始年龄.
主要方法:
- 招募健康的小学儿童参加研究.
- 使用受控衰减参数 (CAP) 测量评估肝脏肥胖症.
- 在两个不同的时间段收集身体成分数据,以跟踪变化并建立参考间隔.
主要成果:
- 用976名体重正常的儿童的数据来确定肝硬化症的参考间隔,将肝硬化症定义为CAP>247dB/m.
- 在一年级儿童中,MASLD的患病率为超重组的0%,肥胖组的16%.
- 到六年级,MASLD的患病率在超重儿童中增加到19%,在肥胖儿童中增加到75%,这表明随着年龄和体重状况的显著增加 (p < 0.001).
结论:
- 肥胖儿童肝硬化查应早在一年级就开始.
- 对于超重的儿童,建议在六年级开始查.
- 这些发现强调了针对儿科MASLD的量身定制,年龄和体重特定的查策略的必要性.
相关概念视频
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
489
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
489
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
165
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
165
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171